In December 2023, Eli Lilly and Company, one of the major GLP-1 receptor agonist companies, announced the availability of Zepbound (tirzepatide) injection, a GLP-1 drug, in the U.S
Especially given the high numbers of people taking the drug who experienced nausea and other gut distress
Retatrutide for weight loss: Clinical trial evidence The phase 1 clinical trials of retatrutide involved 72 individuals with diagnosed type 2 diabetes
All of these factors can contribute to poor production of glutathione (or of the enzymes that help glutathione to do its work), and many also deplete the GSH that the cells produce (by converting it into GSSG)
If you have questions about weight management postpartum, reach out to your provider
The only dual-agonist GLP-1